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Abstract Transgenic mice expressing either human proinsulin
cDNA or mutated proinsulin cDNA in the liver were created. The
human proinsulin cDNA was mutated to generate a protein
cleavable by the ubiquitous prohormone convertase furin, thus
leading to mature insulin peptide. All transgenic lines expressed
human C-peptide in the blood, whose level varied according to
nutritional conditions. High performance liquid chromatography
fractionation of mouse serum revealed that mutant proinsulin
was effectively processed into mature insulin in vivo. This
transgenic mouse model provides a useful tool for further
prospects of gene therapy of insulin-dependent diabetes mellitus.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Insulin-dependent diabetes mellitus (IDDM) is caused by
destruction of the pancreas islet L cells, leading to insulin
de¢ciency. Di¡erent therapeutic strategies based on the sub-
stitution of L cells by an ‘arti¢cial’ insulin producing system in
vivo are currently under investigation. In this context, we have
created transgenic mice that produce human insulin in the
liver in a physiologically regulated manner. The hepatocyte,
like the pancreatic L cell, is a secretory cell and possesses both
the glucose transporter Glut2 and the glucokinase enzyme,
which confers cellular sensitivity to physiological glucose con-
centrations [1,2]. To achieve physiological metabolic control
of insulin production, we used the liver pyruvate kinase (L-
PK) promoter to direct the insulin transgene. The gene encod-
ing the glycolytic enzyme L-PK has previously been shown to
be transcriptionally regulated, positively by glucose and insu-
lin, and inhibited by glucagon or fasting [3,4]. In contrast to L
cells, however, hepatocytes lack the speci¢c proconvertases
required to completely process proinsulin into mature insulin,
the biologically active form of the peptide [5]. To bypass this
inconvenience, we mutated human proinsulin cDNA by gen-
erating in the recombinant product cleavable sites for furin, a
ubiquitous endoprotease [6]. This strategy has been reported
to elicit mature insulin production by a human kidney cell line
in culture [7]. Moreover, a point His-to-Asp mutation was
introduced at position 10 of peptide B to enhance insulin
biological activity [8].
Using this mutated form of proinsulin under the control of
the L-PK gene regulatory sequences, we show here that the
liver of transgenic mice expresses a mature and biologically
active human insulin. Moreover, its production is physiolog-
ically regulated, negatively by fasting and positively by a car-
bohydrate-rich diet.
2. Materials and methods
2.1. Construction of the mutated human proinsulin cDNA
The human wild-type proinsulin cDNA, kindly provided by Dr.
Kevin Docherty (Department of Molecular and Cell Biology, Aber-
deen, UK), was mutated by PCR as described in Fig. 1A. The oligo-
nucleotides used were: INS5, 5P-CTC TCG AGG CCA TGG CCC
TGT GG-3P ; INS3, 5P-CTG CGG TCG ACG TCT AGT TGC AG-
3P ; ASP1, 5P-CAC CAG GTC GGA TCC GCA CAG GTG-3P ;
ASP2, 5P-CTG TGC GGA TCC GAC CTG GTG GAA G-3P ;
BC1, 5P-CTC CCG CTT GGT CCT GGG TGT GTA G-3P ; BC2,
5P-GCA GAG GAC CTG CAG G-3P ; CA1, 5P-CTT CTG CCG GGA
TCC CTC CAG GGC-3P and CA2, 5P-CTG GAG GGA TCC CGG
CAG AAG CTG G-3P. Bold letters indicate restriction sites shown in
Fig. 1A. The resulting plasmid containing the mutated human pro-
insulin cDNA was designated pIPS6.
2.2. Construction of the plasmids
All plasmids were constructed following a standard DNA cloning
procedure [9]. A fragment (from 33200 to +580 bp relative to the
start site of transcription) containing the regulatory sequences of the
L-PK gene, the ¢rst exon, the ¢rst intron and the beginning of the
second exon was mutated by PCR, transforming the ATG site into
TTG (M. Vasseur-Cognet, unpublished results). The resulting EcoRI-
EcoRI fragment was cloned in the bluescript KS vector at the EcoRI
site. This plasmid was designated KS-PK. The L-PK/proINS plasmid
was obtained by inserting a 490 bp Klenow-blunted SpeI-NotI frag-
ment of the proinsulin cDNA into the EcoRV-NotI cut KS-PK. A
Klenow-blunted 330 bp XhoI-SalI fragment of the mutated human
proinsulin from the pIPS6 plasmid was inserted at the EcoRV site
of the bluescript KS vector. A Klenow-blunted 240 bp BamHI-
BclI fragment of the SV40 polyA was cloned at the blunted HindIII
site of this plasmid. A Klenow-blunted XhoI-XhoI 570 bp fragment
containing the mutated proinsulin and the SV40 polyA was obtained
from this plasmid and inserted at the blunted SpeI site of the KS-PK.
The resulting plasmid was designated L-PK/INSm.
A 330 bp XhoI-SalI fragment from the pIPS6 plasmid containing
the mutated human proinsulin cDNA was introduced at the SalI site
in the polylinker of the empty plasmid containing the promoter of
cytomegalovirus (pCMV). This plasmid was designated pCMV-INSm.
The 183PK/CAT construct has been previously described [5]. The
KSV2 CAT plasmid, used as a transfection control, contains the
chloramphenicol acetyltransferase (CAT) reporter gene directed by
the early promoter and enhancer of simian virus 40 (SV40) [10].
2.3. Generation of transgenic mice
The restriction fragments containing the chimeric gene were micro-
injected into fertilized mouse eggs as previously described [11]. Found-
ers were identi¢ed after Southern blot analysis of tail DNAs from
2 week old mice. All subsequent studies were performed on F1 or
F2 mice. Littermates were used as control. All mice were maintained
in accordance with the ‘MinisteØre de l’Agriculture, de la PeŒche et de
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l’Alimentation’ guide for the care and use of laboratory animals (au-
thorization number 04093, o⁄cial Dr. Dominique Daegelen-Proux).
2.4. Nutritional treatment
For metabolic studies, animals were on standard diet or fasted for
24 h and refed with a high carbohydrate diet for 18 h. Mice were
killed between 9.00 and 11.00 h.
2.5. High performance liquid chromatography (HPLC) separation of
serum C-peptide and proinsulin
A 4.6U250 mm C8 Nucleosil column (Touzart and Matignon) was
used with a LKB system. Absorbance was monitored at 226 nm.
Solvent A was Milli-Q water^0.1% tri£uoroacetic acid and solvent
B was 80% acetonitrile^0.1% tri£uoroacetic acid. Using a £ow rate
of 1 ml/min, elution was obtained as follow: isocratic at 30% solvent
B for 10 min, then developing a linear gradient from 30% to 45%
solvent B up to 50 min. Fractions were collected every minute. For
RIA determination, fractions lyophilized were reconstituted in a phos-
phate bu¡er. The HPLC system was standardized using authentic
human C-peptide, insulin and proinsulin.
2.6. Insulin, C-peptide and glucose assays
Blood was collected from the retro-orbital sinus of the mice be-
tween 9.00 and 11.00 h and centrifuged at 800Ug for 10 min. Sera
were kept at 320‡C until further analysis. Urine from mice on the
carbohydrate-rich diet was collected between 9.00 and 11.00 h, kept at
320‡C and centrifuged at 800Ug for 10 min before use. Serum and
urine insulin and C-peptide were measured by RIA with respectively
an anti-insulin serum, recognizing both mouse and human insulin,
and an anti-C-peptide serum recognizing human C-peptide and pro-
insulin (Behring Diagnostic, France). Serum glucose level was meas-
ured using a glucose oxidase colorimetric reaction (Glucose Trinder,
Sigma Diagnostic, USA).
2.7. Cell culture conditions
Hepatocytes from 3 days fasted male Sprague-Dawley rats (180^200
g), isolated by the collagenase perfusion method [4,12,13], were plated
for 4 h onto 10 cm dishes in a ¢nal volume of 10 ml medium 199 (Life
Technologies, Inc.) supplemented with penicillin, streptomycin, and
10% (v/v) dialyzed fetal calf serum. The medium was then replaced
by a serum-free, glucose-free medium containing 10 mM lactate.
2.8. Cell transfections
Transfection of the isolated hepatocytes with the di¡erent plasmids
was performed by lipofection using N-(1-(2,3-dioleoyloxy) propyl)-
N,N,N-trimethylammonium methylsulfate (DOTAP, Boehringer
Mannheim, Mannheim, Germany) according to the manufacturer’s
instructions.
2.9. CAT assays
Cells were harvested 36 h after transfection. CAT activity assays
were performed as described [10,12]. The CAT activity was normal-
ized with respect to the CAT activity of the KSV2 used as a trans-
fection standard. The experiments were performed in duplicate inde-
pendently three times.
2.10. Statistics
Data are given as mean þ S.D. Statistical signi¢cance of di¡erences
between groups was determined by Student’s t-test. The level of sig-
ni¢cance was P6 0.05.
3. Results
3.1. Creation of transgenic mice expressing the wild-type or
the mutated human proinsulin cDNAs in the liver
The mutations described in Fig. 1B were included in the
human proinsulin cDNA. The 5P £anking sequence (33200
bp/+580 bp) of the rat L-PK gene was used to drive the ex-
pression of the wild-type human proinsulin cDNA (L-PK/
proINS) and the mutated proinsulin cDNA (L-PK/INSm) in
the liver of transgenic mice. For each transgene, three di¡er-
ent lines were studied (Table 1). All transgenic animals are
healthy and have a normal reproductive life. Their weight and
glycemia are as in controls.
3.2. The expression of the proinsulin cDNA in L-PK/proINS
and L-PK/INSm mice is dependent on the nutritional
conditions
All transgenic lines exhibited human C-peptide immuno-
reactivity in the serum, re£ecting the production of C-peptide
and/or proinsulin by the liver. As expected, in both L-PK/
proINS mice and L-PK/INSm mice, a high carbohydrate
diet resulted in a signi¢cant increase of serum C-peptide im-
munoreactivity. By contrast, 24 h fasting resulted in the de-
crease of C-peptide (Fig. 2). In the L-PK/INSm mice, the
stimulatory e¡ect of the high carbohydrate diet was far
more important (Fig. 2B). Despite the di¡erent serum C-pep-
tide levels, glycemia values for the di¡erent metabolic states
were similar in controls and transgenic mice (data not shown).
3.3. Mutated human proinsulin is processed by the liver
of transgenic mice
In order to analyze the processing of proinsulin in the liver
of transgenic mice, HPLC and RIA were performed on the
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Fig. 1. Schematic representation of the mutated proinsulin cDNA.
A: Representation of the strategy used to mutate the human proin-
sulin cDNA. The pairs of oligonucleotides (INS5, ASP1) and (CA2,
INS3) were used to obtain the fragments IPS-1 and IPS-4, respec-
tively (see Section 2 for the oligonucleotide sequences). The pairs of
oligonucleotides (INS5, BC1) and (BC2, CA1) were used to obtain
the fragments IPS-2 and IPS-3, respectively. The fragment IPS-5
was obtained after a BamHI cut of IPS-2+3 and was then inserted
between IPS-1 and IPS-4. The resulting vector containing the entire
mutated cDNA was pIPS-6. Arrows indicate new restriction sites.
a indicates mutation at the His-10 site; E indicates mutations at
the junction of the B and C peptides; O indicates mutation at the
junction of the C and A peptides. B: Representation of the muta-
tion incorporated into the human proinsulin cDNA. Four mutations
were incorporated into the human proinsulin cDNA (in bold): His
at position 10 of the B chain was replaced by Asp; two mutations
were incorporated at the processing site between B and C peptides,
converting KTRR into RTKR; LQKR at the processing site be-
tween C and A peptides was converted into RQKR.
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sera of L-PK/proINS mice and L-PK/INSm mice on a carbo-
hydrate-rich diet. The anti-human C-peptide antiserum was
used to selectively distinguish between the human peptides
produced in transgenic mice. One single peak (fractions 43^
47) corresponding to human proinsulin was identi¢ed in the
serum of transgenic mice expressing the wild-type human
proinsulin (Fig. 3A). By contrast, in the serum of mice ex-
pressing the mutated human proinsulin, in addition to a small
peak corresponding to proinsulin (fractions 45^46), one major
peak (fractions 8^15) was identi¢ed (Fig. 3B). This major
peak corresponds to the C-peptide variant derived from the
mutated human proinsulin, which appears earlier than the
wild-type human C-peptide (expected in fractions 19^20) in
the chromatogram. This feature is due to the replacement of
the canonical neutral Leu-32 by a basic Arg residue (Fig. 1).
The complete absence of C-peptide in the L-PK/proINS
mouse serum was in contrast with the minimal processing of
FEBS 19722 15-1-98
Fig. 3. HPLC analysis of C-peptide immunoreactive products in the
serum of transgenic mice. The plain arrow indicates C-peptide peaks
and the dotted arrow indicates proinsulin peaks. A: L-PK/proINS
transgenic mice (line 36). B: L-PK/INSm transgenic mice (line 22).
Fig. 2. Detection of human C-peptide in transgenic mice in di¡erent
nutritional conditions. The human C-peptide immunoreactivity was
evaluated in transgenic lines subjected to 24 h of fasting (F), on a
standard diet (N) or on a high carbohydrate diet (G). A: L-PK/
proINS transgenic lines. B: L-PK/INSm transgenic lines. Bars repre-
sent the mean þ S.D. of all measurements (nv 8).
Table 1
Characteristics of the transgenic lines expressing the human proinsulin cDNA
Line Copies Weight (g) Glucose (g/l) Insulin (WU/ml)
M F N G
L-PK/proINS 30 6 ND ND 1.91 þ 0.26* ND ND
18 16 ND ND ND ND ND
36 30 25.8 þ 3.6* 20.7 þ 0.6* 1.85 þ 0.29* 1.48 þ 1.7* 29.1 þ 4.3*
L-PK/INSm 16 30 28.4 þ 2.6* 22.2 þ 1.2* 1.91 þ 0.29* 15.8 þ 3.2* 27.8 þ 5.6*
46 34 28.8 þ 3.6* 25.7 þ 2.9* 1.76 þ 0.26* ND ND
22 130 26.5 þ 3.3* 22.9 þ 1.4* 1.72 þ 0.41* 15.6 þ 2.6* 28.4 þ 8.8*
Control 25.7 þ 1.7 21.9 þ 1.8 2.02 þ 0.23 14.2 þ 2.2 28 þ 2.8
Each value represent the mean þ S.D. of all measurements (nv 8). M: male; F: female; N: standard diet; G: high carbohydrate diet. *Ps 0.05 vs.
control.
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proinsulin previously reported in the liver [5,14]. Since C-pep-
tide is known to accumulate in the urine, transgenic mouse
urines were analyzed for C-peptide. Expectedly, C-peptide im-
munoreactivity was detected in the urines of L-PK/INSm mice
(5.44 þ 4.27 ng/ml). It was also detected in the urines of L-PK/
proINS mice, although to a lesser extent than in L-PK/INSm
mice (0.69 þ O.6 ng/ml), con¢rming that a low proinsulin
processing can indeed occur in the liver.
Together, these results strongly demonstrate that the mu-
tated proinsulin can be e⁄ciently processed in the liver of
LPK/INSm mice.
3.4. Mutated proinsulin is biologically active
L-PK promoter is controlled by both glucose and insulin
[3,4]. The biological activity of the engineered insulin was then
evaluated by its ability to activate in vitro the transcription of
the L-PK gene. For that purpose, isolated rat hepatocytes
were cotransfected with a CAT reporter gene under the con-
trol of the L-PK promoter (183PK/CAT construct) and either
empty pCMV or pCMV-INSm. CAT activity measured in
transfected cells with the 183PK/CAT gene and the empty
pCMV was strongly increased by 10 nM exogenous human
insulin (Fig. 4). In pCMV-INSm transfected cells, a high CAT
activity was also detected, whose level was dependent on the
amount of transfected plasmid (Fig. 4). These results clearly
demonstrate that insulin produced by the mutated proinsulin
cDNA is a biologically active compound.
3.5. Evaluation of total plasma insulin in transgenic mice
The serum insulin was measured by RIA using an antise-
rum which recognizes both human and mouse insulin. In the
serum of non-transgenic and transgenic mice, insulin levels
were similar, on a standard diet or after a carbohydrate-rich
diet (Fig. 1). Since insulinemia of transgenic mice corresponds
to both human and murine insulin, this result suggests that
endogenous insulin production may be inhibited by the pres-
ence of the new designed peptide. This point is in full agree-
ment with the absence of hypoglycemia observed in transgenic
mice, and the previously reported inhibitory e¡ect of insulin
itself on insulin gene transcription [15].
4. Discussion
The liver provides an excellent target organ to produce ex-
trapancreatic insulin. This approach could be of therapeutic
value for gene therapy of IDDM. Such a strategy requires (i)
insulin gene targeting in the liver, (ii) physiological regulated
expression of the hormone, (iii) processing of proinsulin into
the biologically active insulin, a condition which cannot be
ful¢lled naturally by hepatocytes.
We therefore used the regulatory sequences of the L-PK
gene, which we have previously reported to target numerous
genes in the liver in vivo and to be transcriptionally controlled
by glucose, insulin and glucagon [11,16^18]. Moreover, muta-
tions in the human proinsulin cDNA were generated allowing
cleavage of proinsulin to insulin by furin, an endoprotease
abundantly expressed in the liver. Furin has previously been
shown to process proinsulin into insulin, ex vivo, in a non-
pancreatic L cell line [8]. Our current results clearly demon-
strate that human insulin can also be e⁄ciently produced and
processed in vivo by the liver. Moreover, this production ap-
pears fairly regulated by physiological glucose concentrations.
Other in vivo studies aimed at expressing the insulin gene in
extrapancreatic tissues have already been reported [19,20]. In
the ¢rst, the constitutive CMV promoter was chosen, leading
to a non-regulated synthesis of proinsulin [19]. In the second,
the phosphoenolpyruvate carboxykinase (PEPCK) promoter,
which is positively regulated by glucagon, was used [20]. This
point could be embarrassing in the case of hypoglycemia,
since the resulting glucagon secretion could further induce
insulin release, leading to subsequent aggravation of hypogly-
cemia. By contrast, the transgene inhibition observed in our
fasted transgenic mice overcomes this problem and provides a
safer experimental device. Moreover, these two in vivo studies
used proinsulin, which was not converted into mature insulin.
These strategies would probably have been improved by a
processing system as used in our model. We have demon-
strated that the engineered human insulin produced by our
transgene is biologically active. It e⁄ciently activates the ex-
pression of a reporter gene under the control of the L-PK
gene promoter, which stimulation is strictly dependent on in-
sulin [3,4]. This is in agreement with the results of Groskreutz
et al., demonstrating that the maturation of proinsulin into
insulin by the furin in a kidney cell line leads to a biologically
active peptide [8].
In our study, despite the high level of human C-peptide
detected in transgenic mice, the insulinemia was similar in
transgenic and non-transgenic mice. Note that insulinemia
in transgenic mice corresponded to both murine and human
insulin. This suggests that transgenic expression of human
insulin by the liver could have inhibited the endogenous ex-
pression of pancreatic insulin. Similar observations have been
reported by Bucchini et al. in transgenic mice expressing hu-
man insulin gene in L cells [21]. This point was further sup-
ported by in vitro studies demonstrating the feedback inhib-
ition of insulin gene transcription by insulin itself [15].
In contrast to pancreatic L cells, the constitutive pathway is
the only pathway used by hepatocytes to release circulating
proteins [5]. Thus, the regulated insulin release from the stor-
age vesicles of the L cell that normally occurs after a meal may
probably be absent in the liver cells. In this context, at this
stage of our strategy, engineering hepatocytes for gene ther-
apy of IDDM would probably not provide a means to strictly
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Fig. 4. Stimulatory e¡ect of insulin cDNA expression on L-PK pro-
moter activity. The expression of the 183PK/CAT reporter gene was
evaluated in primary cultured hepatocytes, in the presence of
pCMV alone or with 10 nM exogenous insulin, and increasing
amounts of pCMV-INSm. Similar results were obtained in three in-
dependent experiments.
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maintain glycemia in the normal range. However, it could
allow for the restoration of an endogenous insulin secretion
su⁄cient to avoid acute decompensation.
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